Display options
Cite
Pankov D, Sjöström L, Kalidindi T, et al. . Oncotarget. 2017;8(39):65917-65931doi: 10.18632/oncotarget.19579.
Pankov, D., Sjöström, L., Kalidindi, T., Lee, S. G., Sjöström, K., Gardner, R., McDevitt, M. R., O'Reilly, R., Thorek, D. L. J., Larson, S. M., Veach, D., & Ulmert, D. (2017). . Oncotarget, 8(39), 65917-65931. https://doi.org/10.18632/oncotarget.19579
Pankov, Dmitry, et al. "." Oncotarget vol. 8,39 (2017): 65917-65931. doi: https://doi.org/10.18632/oncotarget.19579
Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D. . Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12. PMID: 29029482; PMCID: PMC5630382.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12.

[No title available]

Oncotarget

Dmitry Pankov, Ludvig Sjöström, Teja Kalidindi, Sang-Gyu Lee, Kjell Sjöström, Rui Gardner, Michael R McDevitt, Richard O'Reilly, Daniel L J Thorek, Steven M Larson, Darren Veach, David Ulmert

Affiliations

  1. Immunology Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  2. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  3. Division of Oncology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
  4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  5. Innovagen AB, Lund, Sweden.
  6. Flow Cytometry Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  7. Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  8. Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  9. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  10. Cancer Molecular and Functional Imaging Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  11. Department of Radiology, Weill Cornell Medical College, New York, NY, USA.

PMID: 29029482 PMCID: PMC5630382 DOI: 10.18632/oncotarget.19579

Abstract

Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is overexpressed in a broad range of malignancies, while absent in most healthy human tissues, making it an attractive diagnostic cancer biomarker and therapeutic target. Although commonly viewed as an intracellular protein, we have demonstrated that PRAME has a membrane bound form with an external epitope targetable with conventional antibodies. We generated a polyclonal antibody (Membrane associated PRAME Antibody 1, MPA1) against an extracellular peptide sequence of PRAME. Binding of MPA1 to recombinant PRAME was evaluated by Enzyme-Linked Immunosorbent Assay (ELISA). Flow cytometry and confocal immunofluorescence microscopy of MPA1 was performed on multiple tumor cell lines. Reverse Transcription Polymerase Chain Reaction (RT-PCR) for

Keywords: PRAME; cancer; immuno-targeting; noninvasive imaging; targeted therapy

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Leuk Res. 2012 Jul;36(7):895-9 - PubMed
  2. Blood. 2006 Dec 15;108(13):4109-17 - PubMed
  3. J Thorac Oncol. 2016 Dec;11(12 ):2208-2217 - PubMed
  4. PLoS One. 2013;8(2):e58052 - PubMed
  5. ESMO Open. 2016 Aug 8;1(4):e000068 - PubMed
  6. J Immunother. 2011 Sep;34(7):556-67 - PubMed
  7. Nucl Med Biol. 2013 Jan;40(1):3-14 - PubMed
  8. Cancer Immunol Immunother. 2011 Sep;60(9):1243-55 - PubMed
  9. Leuk Res. 2010 Dec;34(12):1670-3 - PubMed
  10. Br J Haematol. 1998 Sep;102(5):1376-9 - PubMed
  11. Br J Haematol. 2001 Mar;112(4):916-26 - PubMed
  12. Cell. 2005 Sep 23;122(6):835-47 - PubMed
  13. Immunity. 1997 Feb;6(2):199-208 - PubMed
  14. Nucl Med Biol. 2011 Jul;38(5):675-81 - PubMed
  15. Eur Urol. 2002 Oct;42(4):398-406 - PubMed
  16. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):978-81 - PubMed
  17. Clin Cancer Res. 2004 Jul 1;10(13):4307-13 - PubMed
  18. Leuk Res. 2007 Nov;31(11):1521-8 - PubMed
  19. Leuk Res. 2006 Nov;30(11):1333-9 - PubMed
  20. Am J Hematol. 2011 Jan;86(1):31-7 - PubMed
  21. Nucl Med Biol. 2015 Apr;42(4):375-80 - PubMed
  22. Cancer Res. 1996 Jan 15;56(2):412-8 - PubMed
  23. Mol Cell Proteomics. 2004 Oct;3(10 ):960-9 - PubMed
  24. Breast Cancer Res Treat. 2008 May;109(2):359-65 - PubMed
  25. Cancer Res. 2004 Dec 15;64(24):9167-71 - PubMed

Publication Types

Grant support